Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Synthetic nucleic acid co-transcriptional networks as diagnostic and therapeutic tools

Project description

Innovative tumour diagnostic and therapeutic tools

The diversity of tumours complicates diagnosis and treatment, as a single tumour can present multiple relevant molecular markers. Cost-effective analytical tools are needed to provide fast and effective patient care. The ERC-funded CO-TRANS-NET project will develop synthetic nucleic acid units that respond to tumour biomarkers, offering new tools for biosensing and therapeutics through cell-free in vitro transcription. By combining the programmability of synthetic nucleic acids with the sensitivity of cell-free systems, it will create co-transcriptional networks capable of detecting a range of targets (including proteins, small molecules and antibodies) and triggering the transcription of functional RNA to produce measurable signals or therapeutic drugs. The project aims to develop nanodevices for simultaneous cancer diagnosis and treatment.

Objective

WHY: The heterogeneity of tumors often makes their diagnosis and treatment a very hard task. A single tumor can have many different diagnostically-relevant molecular markers which can also be used to monitor the efficacy of treatment. Innovative, simple, cost-effective, and quantitative analytical tools for diagnostic and therapeutic applications are urgently needed to ensure rapid and appropriate patient care.
WHAT: CO-TRANS-NET project addresses this need by developing synthetic nucleic acid units that can respond to a wide range of tumor biomarkers and can provide innovative tools for biosensing and therapeutics through cell-free in-vitro transcription.
HOW: The ground-breaking idea of CO-TRANS-NET is to harness the high programmability of synthetic nucleic acids together with the high sensitivity and versatility of cell-free systems to develop co-transcriptional networks that, in one pot, through nature-inspired recognition mechanisms, can respond to a variety of targets including proteins, small molecules and antibodies and trigger in-vitro transcription of functional RNA. The transcribed RNA can provide a measurable signal or produce a therapeutic drug. CO-TRANS-NET aims to develop single theranostic nanodevices in which cancer diagnosis and theraphy can be simultaneously achieved- This goes beyond the state of the art and represents a breakthrough in the field of diagnostics, biosensing, synthetic biology and nucleic acid-based therapeutics.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Net EU contribution
€ 1 499 750,00
Address
VIA CRACOVIA 50
00133 Roma
Italy
Region
Centro (IT) Lazio Roma
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 750,00

Beneficiaries (1)